Trending News : U.S. Drug Prices Spark Outrage #usa #medicine #nova #trend #trending #viralvideo

hello and welcome to ecn we deliver you decide Novo Nordisk CEO defends High us drug prices amid Senate scrutiny are these medications truly coste effective greetings ecn listeners today we're diving into a critical issue that's been making waves in the healthc care sector the rising cost of essential medications in the United States at the center of the storm is noo Nordisk the pharmaceutical giant behind two Blockbuster drugs OIC and Wavey which are widely used for diabetes and weight loss management these drugs have sparked intense debate over their pricing especially given the significant difference in what Americans pay compared to the rest of the world Lars ferard jurgenson the CEO of Novo Nordisk recently addressed these concerns in an interview defending the high cost of these medications in the US according to jurgenson the price tags are justified by the broader economic benefits these drugs provide he pointed out that obesity related healthare costs Americans more than $400 billion annually and by offering effective treatments like OIC and Wavey Novo Nordisk is helping to reduce this immense financial burden however this defense hasn't quelled the controversy Senator Bernie Sanders a vocal critic of pharmaceutical pricing has taken particular issue with Novo nordisk's pricing strategy he argues that American consumers are being unfairly ripped off paying up to 10 to 15 times more for these drugs than patients in other countries to put it in perspective while Wavey costs around $1,300 per month in the US it's available for just $92 in the United Kingdom this Stark disparity is at the heart of the upcoming senate committee hearing where jurgenson is expected to testify the high cost of obesity and the debate on drug pricing jurgensen's stance is that the US Healthcare System complexities including the role of insurance companies and Pharmacy benefit managers pbms are partly to blame for the high out-of-pocket costs patients face pbms which negotiate drug prices on behalf of insurers have been accused of inflating costs a claim supported by a recent Federal Trade Commission FTC report that highlighted how these middlemen are driving up drug prices yet despite these justifications many Health policy experts remain skeptical Stacy dusina a professor of Health policy at Vanderbilt University has pointed out that while these drugs can indeed improve health outcomes the current prices are so high that they may actually increase overall health care spending rather than reduce it this raises questions about the long-term sustainability and affordability of such treatments especially when considering how long patients might need to stay on these medications to maintain their health benefits as the debate continues it's clear that the issue of drug pricing in the US is far from resolved jurgensen's upcoming testimony before the senate committee will be a critical moment in this ongoing saga as policy makers healthc Care Professionals and the public seek answers to a complex question how do we balance the cost of innovation with the need for affordable healthare thank you for tuning in to ecn where we strive to bring you the most pressing issues of the day with Clarity and depth if you found this discussion informative please share it leave leave a comment and don't forget to subscribe to our channel for more insightful analysis on the issues that matter most